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Hereditary thrombocytosis is a rare congenital hema-tologic disorder that is caused by single gene defects that affect only the megakaryocytic lineage, show polyclonal hematopoiesis and exhibit either an auto-
somal dominant or autosomal recessive Mendelian inheritance 
pattern.1,2 A growing number of causative variants within the 
thrombopoietin (THPO) gene and the MPL proto-oncogene, 
thrombopoietin receptor (MPL) gene with different clinical 
characteristics have been described throughout the last decades 
and were reviewed by Teofili and Larocca.2 More recently sev-
eral variants within the JAK2 gene have been described in fam-
ilies with hereditary thrombocytosis which are germline and 
located in exons encoding either the kinase or pseudo-kinase 
domain of JAK2.3–6 Here we report a single germline variant in 
the N-terminal FERM domain of JAK2 associated with heredi-
tary thrombocytosis in a Swiss family.
The index patient, a 45-year-old woman, was evaluated for 
long-standing thrombocytosis with a platelet count of approx-
imately 500 × 109 per liter (normal values 130-330 × 109 per 
liter). Her medical history revealed a spontaneous internal 
carotid artery dissection (ICAD) 2 years prior to the evaluation 
leading to a mild but persistent motoric aphasia. Otherwise his-
tory and physical examination were unremarkable and therefore 
not suggestive of any secondary cause of the thrombocytosis. 
On abdominal ultrasound there was no hepatosplenomegaly.
Thus, a work up with regard to a suspected myeloprolifer-
ative neoplasm (MPN) was carried out. The molecular genetic 
analysis in the peripheral blood was negative for JAK2 V617F, 
calreticulin (CALR), MPL W515L/K driver mutations, and 
the BCR-ABL1 translocation. The bone marrow examination 
showed a slightly enhanced but qualitatively normal mega-
karyopoiesis and a quantitatively and qualitatively normal 
myelo- and erythropoiesis. Based on those results, a MPN, in 
particular an essential thrombocythemia, was excluded.
A detailed family history revealed a mild thrombocytosis 
in both healthy daughters of the index patient and therefore 
the possibility of hereditary thrombocytosis was considered. 
After confirmation of a mild thrombocytosis in both daughters 
(platelet count 360 × 109 and 490 × 109 per liter, respectively), 
a next-generation sequencing analysis of the JAK2, THPO, and 
MPL genes was performed in the index patient. A heterozygous 
JAK2 c.668T>C, p.(lle223Thr) variant (Figure 1A), located in 
the N-terminal FERM domain of the JAK2 gene, was detected 
(transcript: NM_004972.3, rs562010686).
This variant was subsequently confirmed with Sanger 
sequencing in both daughters. Based on those findings, a 
diagnostic work up of family members was initiated. All par-
ticipants gave written informed consent. There was no his-
tory of vascular events in affected family members, except 
for the ICAD in the index patient. In addition to the index 
patient and her daughters, mild thrombocytosis was found 
in the mother and in all tested siblings (no data in 1 sister). 
Furthermore, the only child of 1 sister had a platelet count 
within the upper limit of the normal range (301 × 109 per 
liter). The subsequent Sanger sequencing revealed the same 
heterozygous JAK2 c.668T>C, p.(lle223Thr) variant in all 
tested family members (Figure  2), showing an autosomal 
dominant Mendelian inheritance pattern with nearly com-
plete phenotypical penetrance.
In summary, a diagnosis of hereditary thrombocytosis asso-
ciated with a heterozygous JAK2 FERM domain variant, JAK2 
c.668T>C, p.(lle223Thr), was made in this family.
We report a heterozygous JAK2 c.668T>C, p.(lle223Thr) 
variant associated with hereditary thrombocytosis in a 
Swiss family. This very rare variant has previously only been 
described in population studies. The minor allele frequency, 
as listed in the following databases, is gnomAD 0.0008%, 
1000Genomes 0.02%, ExAC 0.0017%; the highest frequency 
is found in South Asian populations: 0.1% in 1000Genomes. 
To our knowledge, no clinical phenotype has been related 
to this variant so far. Nevertheless, a functional analysis 
using different bioinformatic prediction tools tends toward a 
damaging effect of the variant. JAK2 c.668T is a highly con-
served nucleotide (phyloP 4.81). GVGD (v2007) shows class 
C35, SIFT (v6.2.0): deleterious (score: 0.04), MutationTaster 
(v2013): disease causing (prob: 1) PolyPhen2 (v2.2.2r398): 
benign.
So far different single gene variants in the THPO, MPL, 
and JAK2 gene loci have been described as causes of heredi-
tary thrombocytosis.1,2 Depending on the location, the clinical 
relevance in respect to thrombocytosis-associated symptoms 
and the risk of thromboembolic events in particular differs 
widely among these variants. Several high risk variants as 
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well as clinically silent variants have been described in the 
THPO, MPL, and JAK2 gene loci.3–9 It underlines that the 
location of the variant within the gene locus is decisive for the 
clinical course and emphasizes the importance of identifying 
possible new causative variants in correlation to their clinical 
phenotype.
Figure 1. Sequence and location of the variant. (A) Electropherogram trace of the detected JAK2 c.668T>C, p.(lle223Thr) missense variant (top) in com-
parison to the wild-type control (bottom). (B) Locations of germline JAK2 variants associated with hereditary thrombocytosis: black text and arrows indicating 
previously described variants within the kinase- and pseudokinase domain; red text and arrow indicating the novel FERM domain variant. FERM = 4.1 protein ezrin 
radixin moesin; SH2 = Src homology-2.
Figure 2. The JAK2 c.668T>C, p.(lle223Thr) pedigree. Squares indicate male family members; circles indicate female family members. *Index patient. 
#Served as wild-type control. Black shading: family members who are JAK2 c.668T>C, p.(lle223Thr) positive; grey shading: family member without data. 
ICAD = internal carotid artery dissection; n/a = not available; Plts = platelet count (×109 per liter]; VE = history of vascular events.
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In respect to hereditary thrombocytosis, all causative variants 
within the JAK2 gene that have been described so far are gain-
of-function variants and located either in the kinase- or pseu-
do-kinase domain.1,3–6
Interestingly, this heterozygous JAK2 c.668T>C, p.(lle-
223Thr) germline variant identified in our pedigree of heredi-
tary thrombocytosis is located in the N-terminal FERM domain 
of the JAK2 gene locus and to our knowledge has never been 
described in the context of hematologic abnormalities before, 
especially not in hereditary thrombocytosis (Figure 1B).
Published data about the role of JAK2 FERM domain vari-
ants and thrombocytosis are scarce but some in vitro data about 
the regulating role of the JAK2 FERM domain in JAK2 activa-
tion exist. Zhao et al10 demonstrated in vitro that a deletion of 
the JAK2 FERM domain results in a JAK2 hyperactivation state 
in wild-type JAK2 as well as in the presence of JAK2 (V617F) 
mutation, albeit through entirely different mechanisms. In 
wild-type JAK2, they showed an inhibitory effect of the FERM 
domain, as its deletion resulted in a higher basal JAK2 activity. 
In the presence of a JAK2 (V617F) mutation, the deletion of the 
JAK2 FERM domain leads to an increased substrate affinity and 
thus to a functional hyperactivation.10
In addition to this in vitro data, Milosevic Feenstra et al11 
described a sporadic germline JAK2 G335D variant located in 
the FERM domain in a patient with triple-negative MPN but 
they were not able to show any functional alteration of JAK2 
activity associated with this variant. The authors speculate that 
this specific variant is either irrelevant or additional genetic 
events are necessary to exert a clinical phenotype.11
Eder-Azanza et al12 identified 2 more sporadic JAK2 FERM 
domain mutations (p.Y317H and p.N337D) in patients with 
myelofibrosis and CALR mutation and subsequently demon-
strated in vitro that p.Y317H but not p.N337D leads to a JAK2 
gain-of-function state. Whether the FERM domain mutation 
alone or only the combination with the concomitant CALR 
mutation is pathogenic could not be determined in their study.12
More recently, Wu et al13 showed in vitro that a germline 
JAK2 F556V variant which was described in triple-negative 
MPNs increases JAK2 activity through complex posttransla-
tional mechanisms affecting the protein stability of JAK2. They 
demonstrated that F556V disrupts the structural conforma-
tion of the pseudokinase domain and the kinase/pseudokinase 
domain interactions, finally leading to an overactive JAK2 pro-
tein.13 At the moment, it remains unknown whether similar post-
translational mechanisms could contribute to functional effects 
of JAK2 FERM domain mutations. Here, we report for the first 
time the association of a single heterozygous variant in the JAK2 
FERM domain with hereditary thrombocytosis. Thus further in 
vitro investigations regarding possible underlying mechanisms 
would certainly be worth studying.
So far there is no evidence that this variant is associated with 
a relevant clinical phenotype other than mild thrombocytosis 
or a platelet count around the upper limit of the normal range, 
since no relevant thrombocytosis-associated symptoms, and 
thromboembolic events in particular, have been reported in our 
pedigree. There is probably no link between the spontaneous 
ICAD in the index patient and the hereditary thrombocyto-
sis. This is more likely a coincidence as no causal relationship 
between these 2 conditions has been published so far. With 1 
exception, all affected family members are presently younger 
than 60 years; therefore, long-term follow-up will deliver 
more insight regarding the clinical relevance of this germ-
line JAK2 FERM domain variant associated with hereditary 
thrombocytosis.
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